1. Home
  2. PTON vs AUPH Comparison

PTON vs AUPH Comparison

Compare PTON & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peloton Interactive Inc.

PTON

Peloton Interactive Inc.

SELL

Current Price

$4.98

Market Cap

2.4B

ML Signal

SELL

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

SELL

Current Price

$16.57

Market Cap

2.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PTON
AUPH
Founded
2012
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.1B
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
PTON
AUPH
Price
$4.98
$16.57
Analyst Decision
Buy
Buy
Analyst Count
20
7
Target Price
$7.90
★ $17.86
AVG Volume (30 Days)
★ 8.2M
765.8K
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
146.67
★ 5075.00
EPS
0.14
★ 0.53
Revenue
N/A
★ $283,055,000.00
Revenue This Year
N/A
$15.83
Revenue Next Year
N/A
$21.30
P/E Ratio
$36.18
★ $31.36
Revenue Growth
N/A
★ 20.38
52 Week Low
$3.65
$11.30
52 Week High
$8.19
$19.25

Technical Indicators

Market Signals
Indicator
PTON
AUPH
Relative Strength Index (RSI) 47.32 55.95
Support Level $4.78 $15.61
Resistance Level $5.28 $17.02
Average True Range (ATR) 0.18 0.41
MACD 0.04 0.03
Stochastic Oscillator 46.94 74.67

Price Performance

Historical Comparison
PTON
AUPH

About PTON Peloton Interactive Inc.

Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Products derive revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: